|
Raptor Pharmaceutical Corp. (RPTP) Target Price: $6.56 <<< Kursziel von Vista (ende Nov 2009) Raptor announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate ("DR Cysteamine") in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 2% to 5% of the U.S. population. the completion of the initial six-month treatment phase, the study achieved the primary endpoint: mean blood levels of alanine aminotransferase ("ALT"), a common biomarker for NASH, were reduced by over 50%. Additionally, over half of the study participants had achieved normalized ALT levels by the end of the treatment phase. There are no currently approved drug therapies for NASH. These interim results have established proof-of-concept and support further clinical development of DR Cysteamine in NASH. The Company also announced that data from a clinical trial of NGX426, the Company's orally administered non-opioid, AMPA/kainate antagonist, will be presented at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain, to be held November 20-21, 2009 in San Francisco. The objective of the single center, double-blind, randomized study conducted by Mark Wallace, M.D., Professor of Clinical Anesthesiology at the Center for Pain Medicine of the University of California at San Diego, was to demonstrate that the orally administered prodrug NGX426, maintains the analgesic effect previously shown for the active moiety tezampanel. Using a cross-over design, a total of 18 study subjects received single doses of 90 mg of NGX426, 150 mg of NGX426 or placebo in each of three treatment periods. Pain was induced by injecting 250 ug of capsaicin between layers of skin in the forearm at 30 minutes and 120 minutes after dosing. This is yet another valuable asset in Raptor’s clinical pipeline. The Company plans to continue to explore options with NGX426 in the treatment of pain, which potentially include spinning-out or partnering this program to ensure that shareholders receive the maximum value from this potentially groundbreaking drug. In addition, Raptor will potentially have their cystinosis drug on the market in 1H 2011. The fact that Raptor is potentially 18 months away from producing revenues represents a significant opportunity for investors and why we believe Raptor’s share price will increase substantially from current levels. Raptor currently has a balanced pipeline of clinical and preclinical programs. The Company is currently involved in four Phase II clinical programs. The Company’s clinical trials address indications representing large markets worldwide: ALDH2 deficiency and NASH; along with Orphan Indications which typically have a shorter development cycle: cystinosis, and Huntington’s Disease. ALDH2 deficiency and Huntington’s Disease each represent potentially billion dollar markets. |
|
| aus der Diskussion: | RPTP = Top Management und Krass Unterbewertet !!! |
| Autor (Datum des Eintrages): | BrauchGeld (06.01.10 23:42:35) |
| Beitrag: | 7 von 48 (ID:38679929) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |